Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: a real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

2024; Elsevier BV; Volume: 213; Linguagem: Inglês

10.1016/j.ejca.2024.115113

ISSN

1879-0852

Autores

Chiara Molinelli, Marco Bruzzone, Eva Blondeaux, Tommaso Ruelle, Chiara Lanzavecchia, Michelino De Laurentiis, Stefania Russo, Ferdinando Riccardi, Valentina Sini, Francesco Cognetti, Grazia Arpino, Alessandra Fabi, Palma Pugliese, Elena Collovà, Andrea Fontana, Fabio Puglisi, Claudia Bighin, Matteo Lambertini, Lucia Del Mastro,

Tópico(s)

HER2/EGFR in Cancer Research

Referência(s)